Provided by the Meniscus Educational Institute

 
banner

Faculty
Susan Blumel, RN, BSN, OCN
University of Nebraska Medical Center
Section of Hematology/Oncology
Omaha, Nebraska

Nam Hoang Dang, MD, PhD
Nevada Cancer Institute
Las Vegas, Nevada

Amy Goodrich, RN, BSN, MSN, CRNP-AC
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

back to top

Download Activity
Download a Portable Document Format (PDF) version of here Recurrent Indolent NHL: New Strategies for Treatment
(Adobe Acrobat 4.0 or later is required.)

back to top

Instructions for Online Completion
To successfully complete this activity, you must read the entire newsletter, register, and submit your learning assessment and evaluation online, correctly answering 70% of the learning assessment questions. If you provide your e-mail address, you will receive an immediate e-mail notification with a link to your printable statement of credit. If you do not provide your e-mail address, your statement of credit will be mailed to you within 4 weeks.

To register and submit your learning assessment and evaluation form online, click here.

back to top

Provider and Supporter


Provided by the Meniscus Educational Institute
Meniscus                 




back to top

Release and Termination Dates
Release: August 2007
CE available until: August 31, 2008


Supported by an unrestricted educational grant from Cephalon Oncology

cephalon

back to top

Intended Audience
The intended audience for this symposium is nurses who care for patients with non-Hodgkin’s lymphoma and their families. A secondary audience is nurses interested in the topic who may be caring for this population in the future.

back to top

Activity Rationale and Purpose
This newsletter is designed to review the clinical trial data on emerging therapeutic modalities for recurrent indolent NHL and discuss nursing management of patients receiving these treatments. Side effect and toxicity management and patient education issues will be discussed to provide oncology nurses with evidence-based information to utilize in caring for these patients.

back to top

Learning Objectives

After participating in this activity, nurses should be better able to

  • Explain the pathophysiology, diagnosis, and prognosis of indolent NHL and current first-line treatment
  • Identify current and emerging treatment options for patients with recurrent indolent NHL
  • Describe interventions to effectively manage side effects and toxicities of these treatments
  • Outline patient care and patient education priorities in this patient population to ensure improved quality of life

When choosing among continuing education activities, clinicians should select those that are appropriate for their educational needs. Participants in educational activities have the implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional effectiveness. Clinicians should reflect on this activity and its applicability to their own patient population, and then identify and implement appropriate practice changes.

back to top

Continuing Education
Statement of Credit. Participants who successfully complete this activity (including scoring at least 70% on the learning assessment and completing and submitting an evaluation form) will be issued a statement of credit via e-mail or US mail within 4 weeks.

nurseStatement of Credit. This activity for 1.25 contact hours is provided by the Meniscus Educational Institute. The Meniscus Educational Institute is an approved provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

 ANCC

Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 1.25 contact hours.

back to top

Privacy Policy
Meniscus Educational Institute is committed to protecting the privacy of users of our Web site. Please click here to review Meniscus Educational Institute’s privacy policy.

back to top